Santoro, 7,824 patient aspirin late treatment PSM study: 38% lower mortality [p=0.02] https://c19p.org/santoro3
copied to clipboard
Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID‐19: A Propensity Score‐Matched Cohort Analysis of the HOPE‐COVID‐19 Registry
et al., Journal of the American Heart Association, doi:10.1161/JAHA.121.024530
HOPE-COVID-19 PSM retrospective 7,824 patients, comparing prophylactic anticoagulation with and without additional treatment with aspirin in hospitalized patients, showing lower mortality with aspirin treatment.
|
risk of death, 38.0% lower, HR 0.62, p = 0.02, treatment 360, control 2,949.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Santoro et al., 6/22/2022, retrospective, propensity score matching, multivariable, multiple countries, multiple regions, peer-reviewed, 31 authors, study period 16 January, 2020 - 30 May, 2020.
Contact:
natale.brunetti@unifg.it.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.